Images List Premium Download Classic

Immunostimulator

Immunostimulator-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Tumor antigen specific antibodies and tlr3 stimulation to enhance the performance of checkpoint interference therapy ...
Oncoquest Inc.
August 10, 2017 - N°20170226221

The present disclosure relates to a method for inhibiting cancer tumor growth in a patient by administering to the patient a therapeutic monoclonal antibody specific for a tumor associated antigen in combination with at least one immunostimulatory compound, and at least one immune homeostatic checkpoint inhibitor. Also disclosed are uses, compositions and kits thereof.
Immunogenic lhrh composition and use thereof in pigs
United Biomedical, Inc.
August 03, 2017 - N°20170216418

A vaccine composition for castrating pigs, comprising a peptide immunogen and a veterinarily acceptable delivery vehicle or adjuvant, wherein the peptide immunogen comprises (a) a lhrh peptide of seq id no: 1, and (b) at least one t helper epitope selected from a group consisting of seq id nos: 2, 3, 4, and 5, and, optionally, an immunostimulatory peptide of seq in no: 6, wherein the ...
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an ...
Curevac Ag
July 20, 2017 - N°20170202957

The present invention relates to an immunostimulatory composition comprising a) an adjuvant component, comprising or consisting of at least one (m)rna, complexed with a cationic or polycationic compound, and b) at least one free mrna, encoding at least one therapeutically active protein, antigen, allergen and/or antibody, wherein the immunostimulatory composition is capable to elicit or enhance an innate ...
Immunostimulator Patent Pack
Download + patent application PDFs
Immunostimulator Patent Applications
Download + Immunostimulator-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Immunostimulator-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Immunostimulatory combinations of tlr ligands and methods of use
The United States Of America, As Represented By The Secretary, Department Of Health & Human Servic
June 15, 2017 - N°20170165359

The present invention provides immunostimulatory combinations of tlr ligands and therapeutic and/or prophylactic methods that include administering an immunostimulatory combination to a subject. In general, the immunostimulatory combinations described herein can provide an increased immune response compared to other immunostimulatory combinations and/or compositions.
Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof
University Of Southampton
June 08, 2017 - N°20170158771

Through a combination of in vitro and in vivo approaches, the inventors show that human igg2 (h2) delivers unique fcγr-independent agonistic activity to anti-cd40 antibodies and to antibodies specific to other immunostimulatory receptors, including 4-1bb and cd28. Investigation of an anti-human cd40 mab, lob7. 4, revealed that the unique activity of h2 was dependent upon the precise ...
Immunoregulation by anti-ilts antibodies and ilts-binding antibody fragments
Merck Sharp & Dohme Corp.
June 08, 2017 - N°20170158765

Disclosed herein are methods of using anti-ilt5 antibodies and ilt5-binding fragments thereof to induce an immunostimulatory effect in a t cell when such a t cell is contacted with an antigen presenting cell (apc) that has been previously contacted with the anti-ilt5 antibody or ilt5-binding fragment. Also disclosed herein are methods of using anti-ilt5 antibodies and ilt5-binding ...
Immunostimulator Patent Pack
Download + patent application PDFs
Immunostimulator Patent Applications
Download + Immunostimulator-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Immunostimulator-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
Bristol-myers Squibb Company
May 18, 2017 - N°20170137514

The present invention provides isolated monoclonal antibodies that specifically bind lag-3, and have optimized functional properties compared to previously described anti-lag-3 antibodies, such as antibody 25f7 (us 2011/0150892 a1). These properties include reduced deamidation sites, while still retaining high affinity binding to human lag-3, and physical (i. E., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, ...
Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity
The University Of North Carolina At Chapel Hill
May 18, 2017 - N°20170136043

Uses of pyrrolopyrimidines with anti-mer tyrosine kinase activity as anti-infective agents, immunostimulatory and immunomodulatory agents, anti-cancer agents (including against mertk−/− tumors and itd and tkd mutant forms of acute myeloid leukemia (aml)), and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.
Immunostimulatory nanocomplex
National Cheng Kung University
May 11, 2017 - N°20170128593

The present invention relates to an immunostimulatory nanocomplex. The immunostimulatory nanocomplex comprises polyglutamic acid (pga), a first positively charged substance, a second positively charged substance and a dengue viral protein for holding the dengue viral protein inside. The immunostimulatory nanocomplex is characterized by having a nonuniformally and positively charge distribution along a radial direction thereof. The nonuniformally and positively charge ...
Annexin ii compositions and methods
Regents Of The University Of Minnesota
May 11, 2017 - N°20170128570

The present invention provides compositions and methods that involve the 36 kda annexin ii monomer, which has been identified as having immunostimulatory properties. Accordingly, in one aspect, the invention provides compositions that include at least one 36 kda annexin ii monomer or an immunomodulatory fragment thereof. In another aspect, the invention provides methods that include administering to a subject a composition that ...
Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
Biothera, Inc.
April 13, 2017 - N°20170100425

The present invention relates to the combination of soluble β-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble β-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.
Beta-glucan methods and compositions that affect the tumor microenvironment
Biothera, Inc.
April 13, 2017 - N°20170100424

This disclosure relates to the combination of soluble β-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble β-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.
Cell based assay to measure the t-cell stimulating capacity of anti-lag3 antibodies and other agents
Merck Sharp & Dohme Corp.
April 06, 2017 - N°20170097333

The present invention includes a human lag3 functional assay using a jurkat t-cell lymphoma cell line engineered to overexpress lag3 at an optimal level relative to cd3. The assay is useful, for example, for determining the immunostimulatory properties of lag3 modulators (e. G., inhibitors or activators). The optimized lag3/cd3 ratio ensures expression of optimal receptor components on the t-cell ...
Immunostimulator Patent Pack
Download + patent application PDFs
Immunostimulator Patent Applications
Download + Immunostimulator-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Immunostimulator-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Mature dendritic cell compositions and methods for culturing same
Argos Therapeutics, Inc.
April 06, 2017 - N°20170096639

This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (dcs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (idcs) with a first signal comprising an interferon gamma receptor (ifn-γr) agonist and/or a tumor necrosis factor alpha receptor (...
Naturally-occurring cpg oligonucleotide compositions and therapeutic applications thereof
Labyrinth Holdings, Llc
March 30, 2017 - N°20170087247

The present invention relates to combination therapies for the treatment of a variety of disorders in mammals, including hepatic disorders and cancer. The combination of agents includes naturally-occurring (versus synthetic) oligonucleotides, particularly immunostimulatory oligodeoxynucleotides such as cpg odns, obtained from a natural source and one or more extracts from a gram positive bacteria, such as lactobacillus spp.
Immunostimulatory sequence oligonucleotides and methods of using the same
Dynavax Technologies Corporation
March 09, 2017 - N°20170067055

The invention provides immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides.
Uses of starch binding protein (sbp)-tagged immunostimulatory protein
Simpson Biotech Co., Ltd
March 09, 2017 - N°20170065672

The present invention relates to a method for preventing or treating virus and protozoa infection in a subject in need thereof comprising: orally administering to said subject an effective amount of a composition comprising a complex consisting of a starch binding protein (sbp)-tagged immunostimulatory protein and a sbp-binding matrix, wherein the immunostimulatory protein is from ganoderma species. The present ...
Immunostimulatory anti-ceacam1 antibody
Universitaet Duisburg-essen
February 23, 2017 - N°20170051058

An anti-ceacam1 antibody includes at least one antibody heavy chain (vh) domain having antigen binding sites cdr1h, cdr2h and cdr3h, and at least one antibody light chain (vl) domain having antigen binding sites cdr1l, cdr2l and cdr3l. The antigen binding site cdr2h has a sequence homology of at least 80% to the amino acid ...
Immunostimulatory compositions and methods of use thereof
Comvita New Zealand Ltd.
February 23, 2017 - N°20170049825

Immunostimulatory compositions and methods of use are described to either enhance or diminish the immune stimulation effects of a honey or honey isolate by recognition of the presence of type ii arabinogalactan compounds and utilising this knowledge to tailor the concentration of such compounds thereby adjusting the immune stimulation effects.
Immunostimulating agent
Comvita New Zealand Ltd.
February 09, 2017 - N°20170036999

Wherein each symbol is as defined herein, have an immunostimulatory effect and are useful as immunostimulating agents, particularly as adjuvants, and for compositions containing such a compound, and for vaccines containing such a compound and an antigen.
Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
Curevac Ag
February 02, 2017 - N°20170028059

The present invention is directed to a composition or vaccine composition comprising a) an adjuvant component comprising or consisting of at least one immunostimulatory nucleic acid sequence, complexed with a complexing agent; b) an antigen, preferably a protein or peptide antigen and/or a nucleic acid sequence encoding said antigen; and c) a carrier molecule for combined packaging the adjuvant ...
Loading